Project Description: CLAD can be difficult to diagnose and treat. Investigations usually include obtaining a biopsy (sample of tissue) of lung tissue to determine the cause of CLAD.
The ‘Molecular MicroscopeTM Diagnostic System’ has been developed by the Alberta Transplant Applied Genomics Centre (University of Alberta, Canada) to be able to assess the ‘molecular gene signals’ in the cells within tissue biopsies that indicate if there is rejection or some other type of injury occurring, as treatment depends on the exact cause. The biopsy tissue genetic results are read by a computer generated program that has been validated and well tested in 2000 kidney and heart transplant patients. We think it will provide a more accurate way of understanding what is really going on in the lung tissue compare to what information is currently available.
This project is a collaboration between the Alfred Lung Transplant Service and Alberta Transplant Genomics Centre (Transcriptome Sciences). Biopsies from 50 Alfred Lung transplant patients who appear to be developing CLAD, are being collected, processed and sent to the lab in Canada to be assessed by the ‘Molecular MicroscopeTM ‘. Results are then sent back to the Alfred team to evaluate along with all other routine test results to determine how accurate and beneficial the ‘Molecular MicroscopeTM Diagnostic System’ is for diagnosis of chronic rejection-related CLAD in our lung transplant patients. The project will take 2 years to complete.
Project costs: Ethics submission, recruitment and follow-up of patients, collection and processing biopsy specimens, transport of specimens to Canada, collation of results from Molecular Microscope MMDx and clinical results, data analysis.
(The actual Molecular Microscope MMDx costs are being covered by Alberta Transplant Genomics Centre)